Overview

Study for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities

Status:
Completed
Trial end date:
2020-12-09
Target enrollment:
Participant gender:
Summary
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited